Ad
CGEN Short Information Compugen Ltd.
home / stock / cgen / cgen short
Short Information | Compugen Ltd. (NASDAQ:CGEN)
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 3,374,406 |
| Total Actual Volume | 20,506,220 |
| Short Trends | |
|---|---|
| Cover Days | 20 |
| Short Days | 0 |
| No Change Days | 0 |
| Averages | |
|---|---|
| Average Short Volume | 168,720 |
| Average Short Percentage | 16.78% |
Is there a CGEN Short Squeeze or Breakout about to happen?
See the CGEN Short Analysis for free Sign up or Login
Powered by Squeeze Report
CGEN Twenty Trading Day's Volume to Short Volume Chart
CGEN Twenty Trading Day Price Chart
CGEN Short Data Results Days
| Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 01-22-2025 | $2.29 | $2.38 | $2.45 | $2.25 | 1,371,272 | 317,298 | 23.14% |
| 01-21-2025 | $2.37 | $2.27 | $2.45 | $2.13 | 2,158,996 | 318,628 | 14.76% |
| 01-17-2025 | $2.15 | $2.25 | $2.35 | $2.15 | 1,205,287 | 260,501 | 21.61% |
| 01-16-2025 | $2.03 | $2.12 | $2.28 | $2.01 | 2,399,909 | 324,424 | 13.52% |
| 01-15-2025 | $2.01 | $2.01 | $2.05 | $1.92 | 1,132,885 | 148,229 | 13.08% |
| 01-14-2025 | $1.97 | $2 | $2.16 | $1.95 | 2,210,686 | 382,429 | 17.3% |
| 01-13-2025 | $1.67 | $1.99 | $2.0599 | $1.67 | 3,467,350 | 626,853 | 18.08% |
| 01-10-2025 | $1.59 | $1.64 | $1.72 | $1.56 | 1,190,653 | 142,672 | 11.98% |
| 01-08-2025 | $1.61 | $1.59 | $1.625 | $1.52 | 484,163 | 84,810 | 17.52% |
| 01-07-2025 | $1.6 | $1.6 | $1.62 | $1.57 | 240,052 | 49,669 | 20.69% |
| 01-06-2025 | $1.64 | $1.6 | $1.655 | $1.58 | 517,423 | 56,191 | 10.86% |
| 01-03-2025 | $1.68 | $1.6 | $1.68 | $1.59 | 849,853 | 56,694 | 6.67% |
| 01-02-2025 | $1.58 | $1.65 | $1.6999 | $1.58 | 595,207 | 108,225 | 18.18% |
| 12-31-2024 | $1.52 | $1.53 | $1.56 | $1.4801 | 351,310 | 57,823 | 16.46% |
| 12-30-2024 | $1.57 | $1.5 | $1.6 | $1.48 | 721,029 | 171,514 | 23.79% |
| 12-27-2024 | $1.6 | $1.57 | $1.62 | $1.54 | 279,118 | 79,981 | 28.65% |
| 12-26-2024 | $1.58 | $1.63 | $1.645 | $1.56 | 304,949 | 43,045 | 14.12% |
| 12-24-2024 | $1.52 | $1.6 | $1.625 | $1.51 | 224,001 | 38,950 | 17.39% |
| 12-23-2024 | $1.52 | $1.52 | $1.54 | $1.47 | 479,002 | 50,843 | 10.61% |
| 12-20-2024 | $1.53 | $1.53 | $1.59 | $1.5 | 323,075 | 55,627 | 17.22% |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors PR Newswire New approach to harness cytokine biology to treat cancer patients advances to the clinic First ...
-
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies PR Newswire Broad method of use patent protection for COM902, a potential best-in-class reduced&...
-
Compugen Reports Third Quarter 2024 Results PR Newswire Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned wit...